Infinity updates trial data for breast cancer therapy; over 88% achieves cancer reduction
Announcing updated data from its ongoing MARIO-3 clinical study, Infinity Pharmaceuticals (NASDAQ:INFI) said that its combination therapy consisting of eganelisib, for metastatic breast cancer, led 88.6% of patients to show tumor reduction. Infinity (INFI) shares have added ~6.9% in the pre-market.
